TP ANDA HOLDINGS
GenericsTP ANDA HOLDINGS is a generic drug manufacturer focused on Cardiovascular, Immunology, Gastroenterology.
TP ANDA HOLDINGS's Key Drugs
TP ANDA HOLDINGS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
TP ANDA HOLDINGS's Recent FDA Approvals
New NDA/BLA approvals for TP ANDA HOLDINGS over the last two years — novel drugs only, excluding generics and label supplements.
TP ANDA HOLDINGS's Therapeutic Areas
TP ANDA HOLDINGS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Immunology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
TP ANDA HOLDINGS's Top Competitors
TP ANDA HOLDINGS's closest competitors by therapeutic-area and drug-target overlap include Takeda, Novo Nordisk, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
TP ANDA HOLDINGS Pipeline Snapshot
Active clinical trials for TP ANDA HOLDINGS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1971-05-21
- Latest
- 2026-08-12
- Applications
- 44